FDA
-
-
-
-
-
-
-
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
-
-
-
-
-
-
-
EMA begins phased review of Revolution Medicines' daraxonrasib
-
-
-
-
-
-
-
Bernstein SocGen Group Starts Revolution (RVMD) at Market Perform
-
-
-
-
-
-
-
Revolution (RVMD) PT Raised to $169 at H.C. Wainwright
-
-
-
-
-
-
-
Here's the list of top biotech stocks to own for 2026
-
-
-
-
-
-
-
Revolution Medicines receives FDA breakthrough therapy designation for lung cancer drug
-
-
-
-
-
-
-
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations
-
330,553 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

